Development of New Products and Technologies through Open Innovation
First written in FY2019. 6 of 7 entries say "Advanced", first in FY2020. Latest entry: FY2026.
51 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「During the current consolidated fiscal year, we entered into a joint development agreement with Aqualung Carbon Capture, a pioneer in CO2 separation membrane technology (headquartered in Norway; CEO: Andrew Robbins; hereinafter, “Aqualung”), and made a strategic investment in Aqualung.」
Open innovation was expanded to include a strategic investment in Aqualung and a joint development agreement, as well as a strategic partnership with Numat Technologies. - FY2025AdvancedAnnual report
「During the current consolidated fiscal year, through joint research with Hokkaido University on drug delivery technology, we established a technology for selectively delivering mRNA, a type of nucleic acid therapeutic, to the spleen.」
As a specific result of open innovation, the Company established, through joint research with Hokkaido University, a technology for selectively delivering mRNA to the spleen. - FY2024AdvancedAnnual report
「In the environmental contribution field, during the current consolidated fiscal year we began working with AIR WATER INC. to produce formic acid used to preserve pasture grass from CO2 derived from livestock manure biomass. In joint development with Crysalis Biosciences, a U.S. startup developing biomaterials, we are also promoting the biomanufacturing of acetonitrile (a solvent), one of the key raw materials used to produce nucleic acids.」
Open innovation was expanded into specific joint development projects involving formic acid production through effective use of CO2 and the biomanufacturing of a solvent for nucleic acid production. - FY2022AdvancedAnnual report
「During the current consolidated fiscal year, we entered into an agreement with aceRNA Technologies for the joint development of switchable mRNA therapeutics and an investment in the company. Combining the company’s mRNA technology with our drug delivery technology, we will advance the development of therapeutics enabling more stable and precise control of activity in the body.」
As a specific example of open innovation, the Company entered into joint development and investment agreements with aceRNA Technologies and moved into development combining mRNA technology with drug delivery technology. - FY2021AdvancedAnnual report
「During the current consolidated fiscal year, we successfully developed an “ultrathin glass polarizing film” with Nippon Electric Glass Co.,Ltd., featuring excellent continuous production characteristics. It is the world’s first product to integrate Nippon Electric Glass Co.,Ltd.’s 100μm-thick ultrathin glass with the Company’s thin polarizing film through a roll-to-roll process.」
As a specific result of open innovation, the disclosure described the successful development of the world’s first ultrathin glass polarizing film through joint development with Nippon Electric Glass Co.,Ltd. - FY2020AdvancedAnnual report
「The Company’s technology division is actively pursuing open innovation and accelerating the development of various new products and technologies.」
Open innovation continues to be developed and implemented as a means of accelerating new product and technology development. - FY2019First statedAnnual report
「During the current consolidated fiscal year, we actively pursued open innovation and developed various new products and technologies.」
Open innovation was identified for the first time as a means of developing new products and technologies.